Pembrolizumab Shows Promising Results in Advanced Clear Cell Gynecological Cancer Study

Patient Selection and Trial Design

The trial enrolled 48 patients with clear cell gynecologic cancer, including ovarian, endometrial, vaginal, vulval, and cervical cancer. All patients were at least 18 years old and had received one or more prior courses of platinum chemotherapy. They had an ECOG performance status of 0 or 1, measurable disease by RECIST v1.1 criteria, and disease amenable to biopsy.

Exclusion criteria included known autoimmune disease, second malignancy, central nervous system metastases or carcinomatous meningitis, untreated venous thrombosis, and hospitalization for bowel obstruction within the past four weeks.

Treatment Protocol

Participants were administered 200 mg of pembrolizumab intravenously every three weeks for up to 35 cycles.Treatment continued until the occurrence of radiographic progression, unacceptable toxicity, patient withdrawal of consent, physician decision, or completion of 35 cycles.

Primary and Secondary Endpoints

The primary endpoint of the trial was progression-free survival (PFS) at 12 weeks. Secondary endpoints included overall response rate (ORR), duration of response (DOR), PFS, overall survival (OS), safety, and quality of life.

Efficacy Outcomes

Among the 20 patients who achieved confirmed disease control at 12 weeks, the median duration of control from the start of pembrolizumab was 11.7 months. In the 12 patients who experienced a response, the median time to response was 2.2 months, with a median duration of response of 13.1 months.

The one-year PFS rate was 21%, while the two-year PFS rate was 8%. One-year overall survival was 54%, and two-year overall survival was 38%.

Study Limitations

The single-arm design and moderate sample size are key limitations of the study. These factors may impact the generalizability of the findings.

Conclusion and Future Directions

The study highlighted pembrolizumab’s robust and durable clinical benefit in heavily pretreated clear cell gynecologic cancer patients. The treatment was well-tolerated across the study population, and clinical outcomes were superior to those seen with standard-of-care chemotherapy.

Translational research is underway to identify patients who are most likely to benefit from pembrolizumab. Future clinical trials are recommended to explore the use of anti-PD-1 monotherapy or PD-1 inhibitor combinations to address the significant clinical need in this high-risk patient group.